Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study.
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND.: Metaanalyses failed to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lactam monotherapy in patients with sepsis. However, few data exist on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ failure or shock. METHODS.: We prospectively enrolled consecutive patients with severe sepsis or septic shock in 2 intensive care units in the Netherlands from 2011 to 2015. Local antibiotic protocols recommended empirical gentamicin add-on therapy in only 1 of the units. We used logistic regression analyses to determine the association between gentamicin use and the number of days alive and free of renal failure, shock, and death, all on day 14. RESULTS.: Of 648 patients enrolled, 245 received gentamicin (222 of 309 [72%] in hospital A and 23 of 339 [7%] in hospital B) for a median duration of 2 days (interquartile range, 1-3). The adjusted odds ratios associated with gentamicin use were 1.39 (95% confidence interval [CI], 1.00-1.94) for renal failure, 1.34 (95% CI, 0.96-1.86) for shock duration, and 1.41 (95% CI, 0.94-2.12) for day-14 mortality. Based on in vitro susceptibilities, inappropriate (initial) gram-negative coverage was given in 9 of 245 (4%) and 18 of 403 (4%) patients treated and not treated with gentamicin, respectively (P = .62). CONCLUSIONS.: Short-course empirical gentamicin use in patients with sepsis was associated with an increased incidence of renal failure but not with faster reversal of shock or improved survival in a setting with low prevalence of antimicrobial resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include a range of adverse events such as allergic or hypersensitivity reactions, kidney injury, thrombocytopenia, Clostridioides difficile infection, and antimicrobial resistance [101–106].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Acute kidney injury-epidemiology, outcomes and economics
Rewa, O., & Bagshaw, S. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.282 · Cited by 734
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
Nicolau, D. P., Freeman, C. D., Belliveau, P. P., Nightingale, C. H., Ross, J. W., & Quintiliani, R. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.650 · Cited by 641
Paul, M., Lador, A., Grozinsky-Glasberg, S., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344.pub3 · Cited by 377
Kumar, A., Safdar, N., Kethireddy, S., & Chateau, D. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e96b91 · Cited by 340
Klein Klouwenberg, P. M. C., Cremer, O. L., van Vught, L. A., Ong, D. S. Y., Frencken, J. F., Schultz, M. J., Bonten, M. J., & van der Poll, T. (2015) · Critical Care · doi:10.1186/s13054-015-1035-1 · Cited by 281
Self-citationKlouwenberg, P. M. C. K., Ong, D. S. Y., Bos, L. D. J., de Beer, F. M., van Hooijdonk, R. T. M., Huson, M. A., Straat, M., van Vught, L. A., Wieske, L., Horn, J., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182923712 · Cited by 218
Self-citationde Greeff, S. C., & Jw, M. (2017) · Rivm Repository (Netherlands National Institute for Public Health and the Environment) · doi:10.21945/rivm-2017-0056 · Cited by 208
The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs
Tabah, A., De Waele, J., Lipman, J., Zahar, J. R., Cotta, M. O., Barton, G., Timsit, J.-F., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv165 · Cited by 134
Research works printed but not linked: 2
- Nethmap: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in The Netherlands in 2015
- SWAB, 2010, Guidelines for antibacterial therapy of adult patients with sepsis
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Bloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department
Guarino, M., Perna, B., Cesaro, A. E., Maritati, M., Spampinato, M. D., Contini, C., & De Giorgio, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093188 · Cited by 294
Surviving sepsis campaign: research priorities for sepsis and septic shock
Coopersmith, C. M., De Backer, D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martin-Loeches, I., Nunnally, M. E., Antonelli, M., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5175-z · Cited by 281
Rhee, C., Chiotos, K., Cosgrove, S. E., Heil, E. L., Kadri, S. S., Kalil, A. C., Gilbert, D. N., Masur, H., Septimus, E. J., Sweeney, D. A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa059 · Cited by 191
Multidrug-Resistant Sepsis: A Critical Healthcare Challenge
Kumar, N. R., Balraj, T. A., Kempegowda, S. N., & Prashant, A. (2024) · Antibiotics · doi:10.3390/antibiotics13010046 · Cited by 162
“Similar findings were reported in other studies where researchers linked higher mortality with nephrotoxic side effects leading to renal failure [166].”
ResultStrich, J. R., Heil, E. L., & Masur, H. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa221 · Cited by 188
“A recent prospective observational study of patients admitted to the ICU in the Netherlands with severe sepsis and septic shock demonstrated that short courses of adjunctive gentamicin (median duration of 2 days) was associated with an increased risk of renal failure but not with faster reversal of shock or improved s…”
BackgroundUpdate on ventilator-associated pneumonia
Timsit, J., Essaied, W. I., Neuville, M., Bouadma, L., & Mourvillier, B. (2017) · F1000Research · doi:10.12688/f1000research.12222.1 · Cited by 170
Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock
Coopersmith, C. M., Backer, D. D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martín‐Loeches, I., Nunnally, M., Antonelli, M. M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003225 · Cited by 128
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance
Gudiol, C., Albasanz‐Puig, A., Cuervo, G., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636547 · Cited by 132
An approach to antibiotic treatment in patients with sepsis
Martínez, M. L., Plata-Menchaca, E. P., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.47 · Cited by 135
“In a setting in which local ecology and resistance patterns showed a low prevalence of MDR strains, a short course of empirical adjunctive gentamicin was associated with an increased incidence of acute renal failure, without a benefit in survival (92).”
BackgroundHodiamont, C. J., van den Broek, A. K., de Vroom, S. L., Prins, J. M., Mathôt, R. A. A., & van Hest, R. M. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01143-0 · Cited by 88
“Some observational studies found added clinical benefit of gentamicin for specific subpopulations [157–159] while others did not [150, 160, 161], and meta-analyses have shown conflicting conclusions [162, 163].”
BackgroundResultAntibiotic stewardship in the ICU: time to shift into overdrive
Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., Hékimian, G., & Luyt, C.-E. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01134-9 · Cited by 56
Albasanz‐Puig, A., Gudiol, C., Puerta‐Alcalde, P., Ayaz, Ç. M., Machado, M., Herrera, F., Martín‐Dávila, P., Laporte-Amargós, J., Cardozo, C., Akova, M., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00045-21 · Cited by 47
“However, that study mainly included general nonimmunocompromised patients, and only 4% received inadequate empirical antibiotic therapy, probably due to low local levels of antibiotic resistance (22).”
BackgroundBlood Stream Infections from MDR Bacteria
Franco, S. D., Alfieri, A., Pace, M. C., Sansone, P., Pota, V., Fittipaldi, C., Fiore, M., & Passavanti, M. B. (2021) · Life · doi:10.3390/life11060575 · Cited by 53
“Moreover, in a regimen that uses a beta-lactam antibiotic, the introduction of an aminoglycoside has frequently increased the rate of acute renal failure in the acute phase of infection [45,46].”
BackgroundZhang, J., Yan, W., Dong, Y., Luo, X., Miao, H., Maimaijuma, T., Xu, X., Jiang, H., Huang, Z., Qi, L., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1191 · Cited by 53
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Ceftobiprole Perspective: Current and Potential Future Indications
Lupia, T., Pallotto, C., Corcione, S., Boglione, L., & Rosa, F. G. D. (2021) · Antibiotics · doi:10.3390/antibiotics10020170 · Cited by 42
“However, several other studies have found little benefit to a combination treatment and some analyses have shown that patients who undergo combination therapy have an increased risk of side effects [70,71].”
BackgroundHeffernan, A. J., Sime, F. B., Sun, J., Lipman, J., Kumar, A., Andrews, K. T., Ellwood, D. A., Grimwood, K., & Roberts, J. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.020 · Cited by 32
Sieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07653-3 · Cited by 35
Self-citationS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M. W., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01317-1 · Cited by 47
Deelen, J. W. T., Rottier, W. C., Buiting, A. G. M., Dorigo-Zetsma, J. W., Kluytmans, J. A. J. W., van der Linden, P. D., Thijsen, S. F. T., Vlaminckx, B. J. M., Weersink, A. J. L., Ammerlaan, H., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.041 · Cited by 28
Self-citationPrytz, K. L., Prag, M., Fredlund, H., Magnuson, A., Sundqvist, M., & Källman, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236864 · Cited by 26
“By adding only one single dose, the patients still gain the advantage of a wider antibiotic spectrum [14, 15, 36, 37] but the tubular cells may be spared from saturation, and might not develop AKI.”
BackgroundBarbier, F., Dupuis, C., Buetti, N., Schwebel, C., Azoulay, É., Argaud, L., Cohen, Y., Ha, V. H. T., Gainnier, M., Siami, S., et al. (2024) · Critical Care · doi:10.1186/s13054-023-04792-0 · Cited by 30
Sullivan, T., Ichikawa, O., Dudley, J. T., Li, L., & Aberg, J. A. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy091 · Cited by 23
“Given the relatively low prevalence of CRE infections [7], routinely administering CRE therapy to all patients with gram-negative bacteremia may cause unnecessary toxicity and promote widespread resistance to critical last-line antibiotics [8, 9].”
BackgroundAminoglycosides: an update on indications, dosing and monitoring
Moore, H., Yeoh, D. K., Hughes, C. M., Raby, E., & Sandaradura, I. (2025) · Australian Prescriber · doi:10.18773/austprescr.2025.038 · Cited by 21
Corcione, S., Lupia, T., & Rosa, F. G. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.617378 · Cited by 22
Carlsen, S., Boel, J. B., Jarløv, J. O., Gjørup, I. E., Søborg, C., & Arpi, M. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3376-6 · Cited by 20
Cobussen, M., Stassen, P. M., Posthouwer, D., van Tiel, F. H., Savelkoul, P. H. M., Havenith, T., & Haeseker, M. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210012 · Cited by 18
Guillamet, C. V., Burnham, J. P., & Kollef, M. H. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693160 · Cited by 20
Lindberg, O., Geer, L. D., & Chew, M. S. (2020) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001140 · Cited by 17
Renal safety of a single dose of gentamicin in patients with sepsis in the emergency department
Cobussen, M., Haeseker, M. B., Stoffers, J., Wanrooij, V. H. M., Savelkoul, P. H. M., & Stassen, P. M. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.030 · Cited by 17
Karvouniaris, M., Poulakou, G., Tsiakos, K., Chatzimichail, M., Papamichalis, P. A., Katsiaflaka, A., Oikonomou, K., Katsioulis, A., Palli, E., & Komnos, A. (2022) · Antibiotics · doi:10.3390/antibiotics11030405 · Cited by 18
Monotherapy Is Adequate for Septic Shock Due to Gram-Negative Organisms
Klompas, M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002678 · Cited by 16
Recommendations for antibiotic selection for severe nosocomial infections
Mensa, J., Barberán, J., Ferrer, R., Borges-Sa, M., Sedes, P. R., Maseda, E., Oliver, A., Marco, F., Adàlia, R., Aguilar, G., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/126.2021 · Cited by 21
Antibiotic treatment in patients with sepsis: a narrative review
Plata-Menchaca, E. P., Ferrer, R., Ruiz‐Rodríguez, J. C., Morais, R., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1791541 · Cited by 17
Möller, V., Balkhed, Å. Ö., Berild, D., Fredriksson, M. G., Gottfreðsson, M., Holmbom, M., Järvinen, A., Kristjánsson, M., Rydell, U., Sönksen, U. W., et al. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1910338 · Cited by 15
Léone, M., Roberts, J. A., Bassetti, M., Bouglé, A., Lavigne, J.-P., Legrand, M. M., Neely, M. N., Paiva, J.-A., Payen, D. M., Rello, J., et al. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.09.009 · Cited by 17
Benetazzo, L., Delannoy, P.-Y., Houard, M., Wallet, F., Lambiotte, F., Vachée, A., Batt, C., Grunderbeeck, N. V., Nseir, S., Robineau, O., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9110777 · Cited by 14
A nationwide evaluation of antibiotics consumption in Swedish intensive care units
Sjövall, F., Edström, M., Walther, S., & Hanberger, H. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2081717 · Cited by 13
Antibiotic Combination Therapy for Patients With Gram-Negative Septic Shock
Kalil, A. C. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002677 · Cited by 12
López, R., Rello, J., Taccone, F. S., Salem, O. B. H., Bauer, P. R., Seguin, A., de Louw, A. V., Metaxa, V., Klouche, K., Martín‐Loeches, I., et al. (2020) · Shock · doi:10.1097/shk.0000000000001553 · Cited by 11
Aminoglycoside antibiotics: Trying to find a place in this world
Deja, E. N. (2024) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2024.03.002 · Cited by 11
Timing and Spectrum of Antibiotic Treatment for Suspected Sepsis and Septic Shock
Pak, T. R., Rhee, C., & Klompas, M. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.08.001 · Cited by 11
Manquat, E., Dorze, M. L., de Ponfilly, G. P., Benmansour, H., Amarsy, R., Cambau, E., Soyer, B., Chousterman, B. G., & Jacquier, H. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00754-9 · Cited by 9
Current opinion in management of septic shock due to Gram-negative bacteria
Tabah, A., Buetti, N., Barbier, F., & Timsit, J. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000767 · Cited by 11
García-Granja, P. E., López, J., Vilacosta, I., Sarriá, C., Ladrón, R., Olmos, C., Saéz, C., Gómez, I., & Román, J. A. S. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.032 · Cited by 9
Ong, D. S. Y., van Werkhoven, C. H., Cremer, O. L., Thwaites, G. E., & Bonten, M. J. M. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.020 · Cited by 8
Self-citationXu, J., Du, X.-L., Li, D., Li, P., Guo, Q., Xu, X., Hu, F., & Wang, M. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09237-9 · Cited by 9
“Though doubted by some studies [27], this β-lactam-aminoglycosides combination is supported by in vitro and in vivo experimental data [28, 29] and clinical studies [30–33].”
ResultAktuelle Entwicklungen im Bereich Antibiotic Stewardship
Kern, W. V., Horn, S., & Fink, G. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0982-8842 · Cited by 7
Principles of Anti-Infective Therapy
Bradley, J. S., Gerber, J. S., Hersh, A. L., & Long, S. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00289-5 · Cited by 7
Puceta, L., Zilde, A., Freijs, Ģ., Ošs, P., & Dumpis, U. (2025) · Healthcare · doi:10.3390/healthcare13182264 · Cited by 6
Foster, R. A., Troficanto, C., Bookstaver, P. B., Kohn, J. E., Justo, J. A., & Al‐Hasan, M. N. (2019) · Antibiotics · doi:10.3390/antibiotics8010015 · Cited by 6
Antibiotic Thresholds for Sepsis and Septic Shock
Kollef, M. H., & Burnham, J. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1035 · Cited by 7
ddPCR Enhances early diagnosis, treatment, prognosis, and pathogen verification in elderly BSI
Peng, J., Bai, H., Li, Y., Luo, H., Li, J., Dai, H., Wang, H., Meng, T., Zhang, J., Wang, Z., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1605795 · Cited by 5
Tićac, M., Kezele, T. G., & Bubonja‐Šonje, M. (2024) · Antibiotics · doi:10.3390/antibiotics13060569 · Cited by 8
“The appropriate antibiotics are defined as antibiotics to which the causative pathogens are susceptible in vitro or which are appropriate for the suspected site of infection in culture-negative sepsis [8–11].”
BackgroundOptimal and responsible use of antibiotics
Depuydt, P. O., & Waele, J. J. D. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000645 · Cited by 5
Less is more: critically ill status is not a carte blanche for unlimited antibiotic use
Kalil, A. C., & Timsit, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06260-7 · Cited by 5
Important Considerations in the Intensive Care Management of Acute Leukemias
Pourhassan, H., Kareem, W., Agrawal, V., & Aldoss, I. T. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231193955 · Cited by 4
Driessen, R., Groven, R. V. M., van Koll, J., Oudhuis, G. J., Posthouwer, D., van der Horst, I. C. C., Bergmans, D. C. J. J., & Schnabel, R. M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1942543 · Cited by 4
Hovind, M. J., Berdal, J., Dalgård, O., & Lyngbakken, M. N. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf319 · Cited by 3
“…data directly comparing narrow-spectrum β -lactam/gentamicin and broad-spectrum β -lactams in terms of nephrotoxicity are lacking, but several studies have evaluated the risk of kidney injury associated with aminoglycoside therapy in patients with sepsis and serious infections [10–13, 21, 22].”
Surgical Infection Society Research Priorities: A Narrative Review of Fourteen Years of Progress
Mele, T. S., Kaafarani, H. M. A., Guidry, C. A., Loor, M. M., Machado-Aranda, D., Mendoza, A. E., Morris‐Stiff, G. J., Rattan, R., Schubl, S. D., & Barie, P. S. (2020) · Surgical Infections · doi:10.1089/sur.2020.309 · Cited by 5
Empiric aztreonam is associated with increased mortality compared to beta-lactams in septic shock
Jaffa, R. K., Hammer, J., Medaris, L. A., Anderson, W. E., Heffner, A. C., & Pillinger, K. E. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.04.085 · Cited by 3
Antibiotics: it is all about timing, isn’t it?
Klompas, M., & Rhee, C. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000969 · Cited by 4
Lipcsey, M., Castegren, M., Furebring, M., & Sjölin, J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix780 · Cited by 3
Reply to Raoult and Rolain, and to Echols and Tillotson
Kadri, S. S., & Danner, R. L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz186 · Cited by 3
Influence of antibiotic treatment duration on the development of antibiotic resistance
Shahanenko, R., Koziі, N., Shahanenko, V., Авраменко, Н. В., & Taranuha, S. (2023) · Naukovij vìsnik veterinarnoï medicini · doi:10.33245/2310-4902-2023-180-1-113-124 · Cited by 2
Koekenbier, E. L., van den Eijnde, S. E. J. D., van der Linden, P. D., Oosterheert, J. J., Sieswerda, E., Vintcent, L. E. M., Kampschreur, L. M., Bouma, H. R., Ammerlaan, H., Gompelman, M., et al. (2025) · CMI Communications · doi:10.1016/j.cmicom.2025.105075 · Cited by 3
Self-citationSepsis in the intensive care unit: from definitions to outcomes
Driessen, R. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220407rd · Cited by 2
Concerning the use of aminoglycosides in ventilator-associated pneumonia
de Jong, S. Y. M., & Zijlstra, G. J. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00207-8 · Cited by 2
Torisson, G., Madsen, M. B., Davidsen, A. S., Perner, A., Lipman, J., Dulhunty, J. M., & Sjövall, F. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000383 · Cited by 2
Heffernan, A. J., Smedley, A., Stickley, T., Oomen, S., Carrigan, B., Heffernan, R., Woodall, H., Pinidiyapathirage, J. M., & Brumpton, K. (2023) · Australian Journal of Rural Health · doi:10.1111/ajr.13079 · Cited by 1
Goda, A. E., Almosilhy, N. A., & El‐Mahdy, N. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-47243-w · Cited by 2
Eudy, J., Chase, A. M., Sharma, D., Sulaiman, Z. I., Anderson, A., Huggett, A. L., Gloe, L., & Anderson, D. T. (2025) · Antibiotics · doi:10.3390/antibiotics14050497 · Cited by 1
“However, their prospective observation study excluded patients with pulmonary sources and included non-bacteremic patients [44].”
Sepsis and Septic Shock: A Review of Definitions, Pathogenesis, and Treatment
Butler, T., & Levin, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-17148-3_22 · Cited by 2
Руднов, В. А., Bagin, V. A., & Аstafieva, M. N. (2020) · Messenger of Anesthesiology and Resuscitation · doi:10.21292/2078-5658-2020-17-6-54-62 · Cited by 1
Chaudhry, D., Lalwani, L. K., & Manjunath, B. G. (2022) · Springer eBooks · doi:10.1007/978-981-16-9929-0_15 · Cited by 1
Cobussen, M., Havenith, T., Posthouwer, D., van Tiel, F. H., Stassen, P. M., & Haeseker, M. B. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix447 · Cited by 1
Rottier, W. C., Deelen, J. W. T., van Werkhoven, C. H., & Bonten, M. J. M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.09.003 · Cited by 1
Self-citationFrangioti, M. A. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-20102023-170736 · Cited by 2
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply
Chhabra, S., & Mo, Y. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00206-6 · Cited by 1
Ong, D. S. Y., Bonten, M. J. M., & Cremer, O. L. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix782
Self-citationGudiol, C. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.09.001836
“The impact of short courses of aminoglycosides on outcomes has been reported by (among others) Ong and colleagues, who performed a study evaluating the effects of a short add-on course of gentamicin (maximum three days of treatment) on the rates of AKI, reversal of shock, and death, in critically ill patients admitted…”
BackgroundGarcía-Granja, P. E. (2019) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/35080
Sacha, G. L., Srinivas, P., Lam, S. W., & Bass, S. N. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001136
Bruns, N., & Dohna‐Schwake, C. (2020) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-020-01027-2
Balancing between sepsis, AKI and gentamicin in the emergency department
Cobussen, M. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210527mc
Burton, J., & Singer, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-56724-4.00038-1 · Cited by 1
Gram-negative infections – Burden, Antibiotic Resistance and Empiric Treatment
Deelen, J. W. T. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/484
Watkins, R. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732675348.793555344
Resuscitation and Preparation of the Emergency General Surgery Patient
Waibel, B. H., & Kamien, A. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.05.011
Cerenzio, J., Andrade, J., DeAngelis, J., & Truong, J. Q. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241273212
“9,10,15 Despite this, isolation of an MDR organism was not associated with an increased risk of mortality (OR, 1.48 [0.45 – 4.80]). patients in our safety analysis by evaluating time to improvement of AKI which was also similar between groups.”
InfluentialThe Prevalence of Factors Contributing to Drug-Related Complications in Neonates with Sepsis
Moftian, N., Esfandiari, A., Rezaei‐Hachesu, P., Sangsari, R., & Mirnia, K. (2025) · Journal of Reports in Pharmaceutical Sciences · doi:10.5812/jrps-149966
Nielsen, O. W. U., Risum, M. O. S., Nielsen, H. L., & Bodilsen, J. (2025) · Danish Medical Journal · doi:10.61409/a08240568
van den Eijnde, S. E. J. D., Koekenbier, E. L., van der Linden, P. D., Oosterheert, J. J., Bonten, M. J. M., van Werkhoven, C. H., on behalf of the SAGA study group, Ammerlaan, H. S. M., Bouma, H. R., Dofferhoff, A. S. M., et al. (2026) · Trials · doi:10.1186/s13063-026-09722-3
“Adding aminoglycosides extends pathogen coverage and presumably enhances bacterial killing, but may also cause nephrotoxicity and ototoxicity [6, 7].”
Self-citationXu, J., Du, X., Li, D., Li, P., Guo, Q., Xu, X., Hu, F., & Wang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26700922
Xu, J., Du, X., Li, D., Li, P., Guo, Q., Xu, X., Hu, F., & Wang, M. (2024) · Figshare · doi:10.6084/m9.figshare.25530406
Xu, J., Du, X., Li, D., Li, P., Guo, Q., Xu, X., Hu, F., & Wang, M. (2024) · Figshare · doi:10.6084/m9.figshare.25530228
Metadata
- Authors
- Ong, D. S. Y., Frencken, J. F., Klein Klouwenberg, P. M. C., Juffermans, N., van der Poll, T., Bonten, M. J. M., & Cremer, O. L.
- Affiliations
- University Medical Center Utrecht (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-15
- Volume
- 64
- Issue
- 12
- Pages
- 1731-1736
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2594782125
- Cited by
- 109
- References
- 21
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 13 · 2023: 8 · 2022: 10 · 2021: 18 · 2020: 19 · 2019: 10 · 2018: 9 · 2017: 7
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- Center for Translational Molecular Medicine (04I-201)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- gentamicin, sepsis, septic shock, empirical antibiotic therapy, renal failure, shock reversal, mortality, antimicrobial resistance, beta-lactam therapy
- MeSH terms
- Aged, Anti-Bacterial Agents, Female, Gentamicins, Gram-Negative Bacteria, Humans, Intensive Care Units, Male, Middle Aged, Multiple Organ Failure, Prospective Studies, Shock, Septic, Cohort Studies, Logistic Models, Hospital Mortality, Sepsis, Drug Resistance, Multiple, Bacterial, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.